`Sihuang Bailian Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions` is a standardised dried extract powder supplied as a further-processing active pharmaceutical ingredient for veterinary finished dosage forms. The product is not a ready-to-administer medicine; it is blended, granulated, filled, compressed, or reconstituted by licensed manufacturers under Good Manufacturing Practice for active substances. No single harmonised international model number exists for the material. Commercial certificates of analysis typically identify the product by the pharmacopoeial name followed by an intended-grade descriptor—tablet grade, capsule grade, oral powder grade, premix grade, granule grade, or solution-grade feedstock. The dosage-form designation is more operationally significant than a numeric model because it determines particle size distribution, endotoxin limit, residual moisture, and packaging configuration.

Specification control for oral solid and premix grades is organised around identity, extract ratio, loss on drying, total ash, acid-insoluble ash, elemental impurities, microbial enumeration, residual solvents, bulk density, and particle size. Identity is confirmed by high-performance liquid chromatography or thin-layer chromatography against authenticated marker reference materials. Loss on drying is determined using USP <731> or the corresponding general chapter of the Chinese Veterinary Pharmacopoeia. Elemental impurities are assessed by inductively coupled plasma mass spectrometry under USP <233>. Residual solvents are evaluated by gas chromatography under USP <467>. Microbial limits are interpreted using USP <2021> and USP <2022>. These methods define the control framework rather than the therapeutic claim.

What Limits the Use of the Same API Grade in Injectable Solutions and Tablet Blends?

Parenteral-grade material is not defined solely by particle fineness. The critical divergences are bacterial endotoxin burden, bioburden, insoluble particulate matter, and filterability. Tablet and capsule production tolerate a wider particle size distribution because downstream dry blending and wet granulation reduce segregation risk. Solution-grade powder is usually jet-milled to a D90 below 30 μm and controlled for insoluble particulate count after reconstitution. For injectable manufacture, the reconstituted liquid is prefiltered through a 0.45 μm clarifying membrane and then through a 0.22 μm sterilising-grade filter before aseptic filling. Endotoxin acceptance is calculated from the intended dose and species-specific limit under USP <85> or VICH GL70. In small-volume parenterals the reconstituted powder may need to meet an endotoxin level not above 0.5 EU/mg; oral-grade powder often exceeds this level or produces colloidal fouling that reduces filter capacity below acceptable throughput. Published product-specific parenteral data for this herbal preparation is limited.

In tablet and granule manufacture, the powder is blended with microcrystalline cellulose, croscarmellose sodium, and a binder solution in a high-shear mixer. The wet mass is passed through a 1.2–2.0 mm screen and dried in a fluid-bed dryer with inlet air temperature below 60 °C to protect heat-labile constituents. Incoming powder with moisture above 5.0% w/w by USP <731> tends to cake during storage and produces tablet hardness variation. Moisture below 2.0% w/w increases electrostatic charging and dusting on rotary tablet presses operating above 50 rpm. Granulation end-point is controlled by product temperature rather than time alone. Loss on drying measured after cooling to 25 °C should vary by no more than ±0.3% w/w between top and bottom samples of the fluid-bed dryer; larger variation indicates inadequate bed fluidisation.

For capsule filling on dosator or tamping-pin machines, the granulated blend is usually adjusted to a Carr index below 25%. Direct filling of the ungranulated powder is limited by low bulk density and high interparticle cohesion. The dry blend is lubricated with magnesium stearate at 0.5–1.0% w/w; lubricant above 1.5% w/w can delay dissolution because a hydrophobic film forms around extract-containing granules. Tablets are compressed on rotary presses with pre-compression force and main compression force selected according to tablet diameter; high proportions of herbal extract powder may laminate if granule moisture falls below 2.5% w/w. Finished tablets are evaluated for content uniformity under USP <905> and dissolution under USP <711> using apparatus II at 50 rpm and 37 ± 0.5 °C.

Solution preparation begins with reconstitution in purified water at 40–50 °C under high-shear dispersion. The pH is adjusted with citrate or phosphate buffer because extract constituents can precipitate below pH 4.0 or degrade above pH 9.0. The liquid is cooled, filtered, and sampled for clarity. If oral-grade powder is used for a solution, filtration may require 2–3 times the membrane area of solution-grade feedstock because of fine colloidal polysaccharides. Therefore, solution-grade material is specified with a low insoluble particulate count in the redispersed liquid and is tested under USP <788> after reconstitution and filtration. Powders and granules intended for drinking water or feed are tested for reconstitution time by dispersing a 5 g sample in 100 mL of water at 25 °C; sieve retention is recorded according to the manufacturer's internal method.

When Oral Premix Granulation Reaches a Feed Rate Constraint

Premix production on continuous screw conveyors is sensitive to flow. Bulk density below 0.35 g/cm³ creates hopper bridging and reduces feed accuracy to less than ±5% of target weight. Dry granulation with a roller compactor is then used to produce free-flowing granules with a target size of 0.2–0.8 mm. Roller compaction pressure is maintained between 30 and 80 kN per roll width depending on compressibility; higher pressure can densify the material above 0.70 g/cm³, which slows wetting and dispersion in drinking water. In feed-mill premix lines, batch-to-batch variance in extract ratio is a larger source of assay drift than blending time. The premix is therefore prepared in two stages: the API is first mixed with a small-volume carrier such as calcium carbonate or lactose, and the pre-blend is then diluted into the complete feed or mineral premix.

A Comparison with Crude Botanical Powders and Synthetic Chemical APIs

The principal difference between Sihuang Bailian Powder Veterinary Grade API and a crude plant powder is that the API is extracted, concentrated, dried, milled, and tested for extract ratio and marker profile. Crude powder retains fibre, starch, and plant matrix components that dilute actives and produce unpredictable particle size. The veterinary grade API is also controlled for microbial enumeration and elemental impurities, which reduces downstream decontamination burden. Compared with a single-entity synthetic API, this material has a wider particle size distribution and requires marker-profile rather than single-analyte assay. It also exhibits multi-component interactions that affect dissolution, solution clarity, and pH stability; substitution of a single synthetic marker compound is not bioequivalent without comparative dissolution and target-species studies.

Residual Solvent Control Is the Principal Bottleneck in Solution-Grade Supply

Extraction and drying may introduce methanol, ethanol, acetone, or ethyl acetate if solvent-based purification is used. Residual solvent levels above the limits of USP <467> Class 3 are a frequent cause of batch rejection in solution-grade supply because the API is dissolved before terminal filtration. The powder is therefore dried under vacuum below 80 °C and sampled for gas chromatography before release. If residual solvent exceeds the approved limit, the batch cannot be salved by blending with compliant material in all jurisdictions; some pharmacopoeial systems prohibit blending non-compliant and compliant lots to reduce excipient or solvent residues. Manufacturers should specify the solvent grade and drying process on the supplier questionnaire to prevent injectable-process failures.

Moisture-barrier packaging is required because the powder is hygroscopic. Aluminium foil laminate with desiccant is used when loss on drying must remain below 5.0% w/w during a 24-month shelf life under long-term storage at 25 °C/60% RH and accelerated testing at 40 °C/75% RH per VICH GL3. Storage in low-density polyethylene bags alone is not appropriate at relative humidity above 60% because water activity above 0.6 accelerates microbial proliferation. Oxidative marker degradation is reduced by nitrogen-flushed packaging and protection from direct sunlight; light-exposure testing follows ICH Q1B or the corresponding veterinary stability guidance. The powder should not be combined with strong alkalies, oxidising agents, or amine-based additives in the same processing step unless compatibility has been demonstrated, because pH shifts above 9.0 can degrade the marker profile and produce precipitation in reconstituted solutions.